AbbVie Inc. buy gerihouse
Summary
This prediction ended on 14.04.15 with a price of €57.47. The BUY prediction by gerihouse finished with a performance of 1.83%. gerihouse has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AbbVie Inc. | -1.958% | -1.958% | 10.029% | 56.706% |
| iShares Core DAX® | 4.094% | 4.888% | 17.421% | 22.413% |
| iShares Nasdaq 100 | 1.424% | -0.445% | 37.618% | 58.203% |
| iShares Nikkei 225® | -1.572% | -4.911% | 12.951% | 7.961% |
| iShares S&P 500 | 1.822% | 0.776% | 29.182% | 49.914% |
Comments by gerihouse for this prediction
In the thread AbbVie Inc. diskutieren
Kaufen, Kaufen!
Bei AbbVie kann man jetzt wieder einsteigen. Vor den Zahlen heute kaufen!
AbbVie is set to report Q4 earnings on Friday before the market opens. Analysts expect the research based pharmaceutical company to report revenue of $5.36 billion and earnings per share ("eps") of $0.86. The revenue estimate represents 7% growth sequentially. For its most recent quarter the company had revenue of $5.0 billion and eps of $0.31. Below are the company's historical financial result
With a market capitalization of $101 billion, AbbVie currently trades at about 27x trailing earnings. The P/E ratio reflects the promise of Viekera Pak. The Express Scripts win was encouraging; however, investors will be keen to determine whether doctors are prescribing Viekera Pak in large enough amounts to meet its $2 billion sales projection for 2015. If so, it could drive the stock dramatically higher. I am long the stock.
